A regenerative approach for bone repair in congenital pseudarthrosis of the tibia associated or not associated with type 1 neurofibromatosis: correlation between laboratory findings and clinical outcome

References

• Vander Have KL, Hensinger RN, Caird M, Johnston C, Farley FA. Congenital pseudarthrosis of the tibia. J Am Acad Orthop Surg. 2008;16:228–36.
   PubMedGoogle Scholar
• Feldman DS, Jordan C, Fonseca L. Orthopaedic manifestations of neurofibromatosis type 1. J Am Acad Orthop Surg. 2010;18:346–57.
   PubMedGoogle Scholar
• Hefti F, Bollini G, Dungl P, Fixsen J, Grill F, Ippolito E, . Congenital pseudarthrosis of the tibia: history, etiology, classification, and epidemiologic data. J Pediatr Orthop B. 2000;9:11–5.
   PubMed Web of Science ®Google Scholar
• Ohnishi I, Sato W, Matsuyama J, Yajima H, Haga N, Kamegaya M, . Treatment of congenital pseudarthrosis of the tibia: a multicenter study in Japan. J Pediatr Orthop. 2005;25:219–24.
   PubMed Web of Science ®Google Scholar
• Carney BT, Daniels CL. A retrospective review of congenital pseudarthrosis of the tibia. Iowa Orthop J. 2002;22:57–60.
   PubMedGoogle Scholar
• Dominici M, Le Blanc K, Mueller I, Slaper-Cortenbach I, Marini F, Krause D, . Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy. 2006;8:315–7.
   PubMed Web of Science ®Google Scholar
• Brooke G, Cook M, Blair C, Han R, Heazlewood C, Jones B, . Therapeutic applications of mesenchymal stromal cells. Semin Cell Dev Biol. 2007;18:846–58.
   PubMed Web of Science ®Google Scholar
• Novicoff WM, Manaswi A, Hogan MV, Brubaker SM, Mihalko WM, Saleh KJ. Critical analysis of the evidence for current technologies in bone-healing and repair. J Bone Joint Surg Am. 2008;90(S1):85–91.
   PubMedGoogle Scholar
• Hernigou P, Mathieu G, Poignard A, Manicom O, Beaujean F, Rouard H. Percutaneous autologous bone-marrow grafting for nonunions. Surgical technique. J Bone Joint Surg Am. 2006;88(S1):322–7.
   PubMedGoogle Scholar
• Garg NK, Gaur S. Percutaneous autogenous bone-marrow grafting in congenital tibial pseudarthrosis. J Bone Joint Surg Br. 1995;77:830–1.
   PubMedGoogle Scholar
• Kitoh H, Kitakoji T, Tsuchiya H, Mitsuyama H, Nakamura H, Katoh M, . Transplantation of marrow-derived mesenchymal stem cells and platelet-rich plasma during distraction osteogenesis: a preliminary result of three cases. Bone. 2004;35:892–8.
   PubMed Web of Science ®Google Scholar
• Cho TJ, Choi IH, Lee KS, Lee SM, Chung CY, Yoo WJ, . Proximal tibial lengthening by distraction osteogenesis in congenital pseudarthrosis of the tibia. J Pediatr Orthop. 2007;27:915–20.
   PubMedGoogle Scholar
• Tikkanen J, Leskelä HV, Lehtonen ST, Vähäsarja V, Melkko J, Ahvenjärvi L, . Attempt to treat congenital pseudarthrosis of the tibia with mesenchymal stromal cell transplantation. Cytotherapy. 2010;12:593–604.
   PubMed Web of Science ®Google Scholar
• Leskelä HV, Kuorilehto T, Risteli J, Koivunen J, Nissinen M, Peltonen S, . Congenital pseudarthrosis of neurofibromatosis type 1: impaired osteoblast differentiation and function and altered NF1 gene expression. Bone. 2009;44:243–50.
   PubMed Web of Science ®Google Scholar
• Granchi D, Devescovi V, Baglìo SR, Leonardi E, Donzelli O, Magnani M, . Biological basis for the use of autologous bone marrow stromal cells in the treatment of congenital pseudarthrosis of the tibia. Bone. 2010;46:780–8.
   PubMedGoogle Scholar
• Kolanczyk M, Kossler N, Kühnisch J, Lavitas L, Stricker S, Wilkening U, . Multiple roles for neurofibromin in skeletal development and growth. Hum Mol Genet. 2007; 16:874–86.
   PubMedGoogle Scholar
• Schindeler A, Little DG. Recent insights into bone development, homeostasis, and repair in type 1 neurofibromatosis (NF1). Bone. 2008;42:616–22.
   PubMedGoogle Scholar
• Kuorilehto T, Nissinen M, Koivunen J, Benson MD, Peltonen J. NF1 tumor suppressor protein and mRNA in skeletal tissues of developing and adult normal mouse and NF1-deficient embryos. J Bone Miner Res. 2004;19:983–9.
   PubMedGoogle Scholar
• Neurofibromatosis. NIH Consens Statement Online 1987 Jul 13–15;6(12):1–19.http://consensus.nih.gov/1987/1987Neurofibramatosis064html.htm 09/10/2009.
   Google Scholar
• Dohan Ehrenfest DM, Rasmusson L, Albrektsson T. Classification of platelet concentrates: from pure platelet-rich plasma (P-PRP) to leucocyte- and platelet-rich fibrin (L-PRF). Trends Biotechnol. 2009;27:158–67.
   PubMed Web of Science ®Google Scholar
• Savarino L, Cenni E, Tarabusi C, Dallari D, Stagni C, Cenacchi A, . Evaluation of bone healing enhancement by lyophilized bone grafts supplemented with platelet gel: a standardized methodology in patients with tibial osteotomy for genu varus. J Biomed Mater Res B Appl Biomater. 2006;76:364–72.
   PubMedGoogle Scholar
• Charnley J. Congenital pseudarthrosis of the tibia treated by intramedullary nail. J Bone Joint Surg Am. 1956;38:283–90.
   PubMedGoogle Scholar
• Ciapetti G, Ambrosio L, Marletta G, Baldini N, Giunti A. Human bone marrow stromal cells: in vitro expansion and differentiation for bone engineering. Biomaterials. 2006;27:6150–60.
   PubMed Web of Science ®Google Scholar
• Granchi D, Baglìo SR, Amato I, Giunti A, Baldini N. Paracrine inhibition of osteoblast differentiation induced by neuroblastoma cells. Int J Cancer. 2008;123:1526–35.
   PubMedGoogle Scholar
• Granchi D, Ochoa G, Leonardi E, Devescovi V, Baglìo SR, Osaba L, . Gene expression patterns related to osteogenic differentiation of bone marrow-derived mesenchymal stem cells during ex vivo expansion. Tissue Eng Part C Methods. 2010;16:511–24.
   PubMed Web of Science ®Google Scholar
• Mouritzen P, Noerholm M, Nielsen PS, Jacobsen N, Lomholt C, . ProbeLibrary: a new method for faster design and execution of quantitative real-time PCR. Nat Methods. 2005;4:313–6.
   Google Scholar
• Hernigou P, Beaujean F. Bone marrow in patients with pseudarthrosis. A study of progenitor cells by in vitro cloning. Rev Chir Orthop Reparatrice Appar Mot. 1997;83:33–40.
   PubMedGoogle Scholar
• Seebach C, Henrich D, Tewksbury R, Wilhelm K, Marzi I. Number and proliferative capacity of human mesenchymal stem cells are modulated positively in multiple trauma patients and negatively in atrophic nonunions. Calcif Tissue Int. 2007;80:294–300.
   PubMedGoogle Scholar
• Hofmann A, Ritz U, Hessmann MH, Schmid C, Tresch A, Rompe JD, . Cell viability, osteoblast differentiation, and gene expression are altered in human osteoblasts from hypertrophic fracture non-unions. Bone. 2008;42:894–906.
   PubMed Web of Science ®Google Scholar
• Garrison KR, Shemilt I, Donell S, Ryder JJ, Mugford M, Harvey I, . Bone morphogenetic protein (BMP) for fracture healing in adults. The Cochran Library. 2010;6:1–52.
   Google Scholar
• Anticevic D, Jelic M, Vukicevic S. Treatment of a congenital pseudarthrosis of the tibia by osteogenic protein-1 (bone morphogenetic protein-7): a case report. J Pediatr Orthop B. 2006;15:220–1.
   PubMedGoogle Scholar
• Fabeck L, Ghafil D, Gerroudj M, Baillon R, Delincé P. Bone morphogenetic protein 7 in the treatment of congenital pseudarthrosis of the tibia. J Bone Joint Surg Br. 2006;88:116–8.
   PubMedGoogle Scholar
• Lee FY, Sinicropi SM, Lee FS, Vitale MG, Roye DP Jr, Choi IH. Treatment of congenital pseudarthrosis of the tibia with recombinant human bone morphogenetic protein-7 (rhBMP-7). A report of five cases. J Bone Joint Surg Am. 2006;88:627–33.
   PubMedGoogle Scholar
• Kujala S, Vähäsarja V, Serlo W, Jalovaara P. Treatment of congenital pseudarthrosis of the tibia with native bovine BMP: a case report. Acta Orthop Belg. 2008;74:132–6.
   PubMedGoogle Scholar
• Richards BS, Oetgen ME, Johnston CE. The use of rhBMP-2 for the treatment of congenital pseudarthrosis of the tibia: a case series. J Bone Joint Surg Am. 2010;92:177–85.
   PubMedGoogle Scholar
• Kinsella CR Jr, Cray JJ, Durham EL, Burrows AM, Vecchione L, Smith DM, . Recombinant human bone morphogenetic protein-2-induced craniosynostosis and growth restriction in the immature skeleton. Plast Reconstr Surg. 2011;127:1173–81.
   PubMedGoogle Scholar
• Oetgen ME, Richards BS. Complications associated with the use of bone morphogenetic protein in pediatric patients. J Pediatr Orthop. 2010;30:192–8.
   PubMedGoogle Scholar
• Gandhi A, Bibbo C, Pinzur M, Lin SS. The role of platelet-rich plasma in foot and ankle surgery. Foot Ankle Clin. 2005;10:621–37.
   PubMedGoogle Scholar
• Cenni E, Savarino L, Perut F, Fotia C, Avnet S, Sabbioni G. Background and rationale of platelet gel in orthopaedic surgery. Musculoskelet Surg. 2010;94:1–8.
   PubMedGoogle Scholar
• Arvidson K, Abdallah BM, Applegate LA, Baldini N, Cenni E, Gomez-Barrena E, . Bone regeneration and stem cells. J Cell Mol Med. 2011;15:718-46.
   PubMed Web of Science ®Google Scholar
• Griffin XL, Smith CM, Costa ML. The clinical use of platelet-rich plasma in the promotion of bone healing: a systematic review. Injury. 2009;40:158–62.
   PubMed Web of Science ®Google Scholar
• Tschon M, Fini M, Giardino R, Filardo G, Dallari D, Torricelli P, . Lights and shadows concerning platelet products for musculoskeletal regeneration. Front Biosci (Elite Ed). 2011;3:96–107.
   PubMedGoogle Scholar
• Visser LC, Arnoczky SP, Caballero O, Kern A, Ratcliffe A, Gardner KL. Growth factor-rich plasma increases tendon cell proliferation and matrix synthesis on a synthetic scaffold: an in vitro study. Tissue Eng Part A. 2010;16:1021–9.
   PubMedGoogle Scholar
• Huang W, Yang S, Shao J, Li YP. Signaling and transcriptional regulation in osteoblast commitment and differentiation. Front Biosci. 2007;2:3068–92.
   Google Scholar
• Ogata Y. Bone sialoprotein and its transcriptional regulatory mechanism. J Periodontal Res. 2008;43:127–35.
   PubMed Web of Science ®Google Scholar
• Motamed K. SPARC (osteonectin/BM-40). Int J Biochem Cell Biol. 1999;31:1363–6.
   PubMed Web of Science ®Google Scholar
• Kurtz A, Martuza RL. Antiangiogenesis in neurofibromatosis 1. J Child Neurol. 2002;17:578–84.
   PubMedGoogle Scholar
• Kawachi Y, Xu X, Ichikawa E, Imakado S, Otsuka F. Expression of angiogenic factors in neurofibromas. Exp Dermatol. 2003;12:412–7.
   PubMedGoogle Scholar
• Mashour GA, Ratner N, Khan GA, Wang HL, Martuza RL, Kurtz A. The angiogenic factor midkine is aberrantly expressed in NF1-deficient Schwann cells and is a mitogen for neurofibroma-derived cells. Oncogene. 2001;20: 97–105.
   PubMed Web of Science ®Google Scholar